Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.73 (
urokinase-type plasminogen activator
)
10,685
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Janus kinases Jak1 and Tyk2 play an important role in
urokinase-type plasminogen activator
(
uPA
)-dependent signaling. We have recently demonstrated that both kinases are associated with the
uPA
receptor (uPAR) and mediate
uPA
-induced activation of signal transducers and activators of transcription (Stat1,
Stat2
, and Stat4) in human vascular smooth muscle cells (VSMC). Janus kinases are not only required for Stat activation but may also interfere with other intracellular signaling pathways. Here we report that in VSMC, Tyk2 interacts with a downstream signaling cascade involving phosphatidylinositol 3-kinase (PI3-K). We demonstrate that
uPA
induces PI3-K activation, which is abolished in VSMC expressing the dominant negative form of Tyk2. The regulatory subunit p85 of PI3-K co-immunoprecipitates with Tyk2 but not with Jak1, Jak2, or Jak3, and
uPA
stimulation increases the PI3-K activity in Tyk2 immunoprecipitates. Tyk2 directly binds to either of the two Src homology 2(SH2)p85 domains in a
uPA
-dependent fashion. We provide evidence that the Tyk2-mediated PI3-K activation in response to
uPA
is required for VSMC migration. Thus, two unrelated structurally distinct specific inhibitors of PI3-K, wortmannin and LY294002, prevent VSMC migration induced by
uPA
. No migratory effect of
uPA
was observed in VSMC expressing the dominant negative form of Tyk2. Our results underscore the versatile function of Tyk2 in
uPA
-related intracellular signaling and indicate that PI3-K plays a selective role in the regulation of VSMC migration.
...
PMID:Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. 1099 43